CLL Society
WHAT’S NEW
Your connection to the most current news, information, and data about Chronic Lymphocytic Leukemia.
We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
Living with CLL
Dietary and Herbal Supplement Use Among Patients with CLL
Dietary and herbal supplement use is common among patients with CLL with half of patients reporting current or past use.
Genetic Risk Factors and Response to Different CLL Therapies
Patients with CLL and high-risk genetic factors had better outcomes on acalabrutinib-venetoclax combination therapies than on chemoimmunotherapy.
Fixed-Duration Less Expensive Than Continuous CLL Therapy
Researchers used modeling to show that fixed-duration therapy would reduce five-year costs for patients with CLL compared with continuous therapy.
A Novel Bispecific T-Cell Engager Targeting ROR1 for CLL
NVG-111 has a manageable safety profile with side effects typical of immunotherapies and preliminary evidence of efficacy in its first clinical trial.
Infection Risk Factors in Patients with CLL on BTK Inhibitors
Patients with CLL on BTK inhibitor therapy develop mostly minor infections, but prior pneumonia was a risk factor for developing severe infections.
Dr. Ratner offers his memories through the lens of a physician with CLL who specializes in the care of older adults and as a Support Group facilitator.
WHAT'S NEW IN CLL / SLL
Ask the Expert is now Trusted Care Exchange
You may notice a new name on one of CLL Society’s trusted resources.
Our Ask the Expert program is now called Trusted Care Exchange for CLL / SLL. While the name has changed, the program remains the same helpful resource for patients and care partners looking for trustworthy answers to general questions about CLL or SLL.
Through Trusted Care Exchange, you can submit a question and receive guidance from a vetted advanced practitioner. Questions often relate to symptoms, lab results, medications, side effects, nutrition, and other aspects of living with CLL or SLL.
For those who may benefit from more personalized, in-depth support, CLL Society also offers Expert Access. This program connects patients with a physician for a free second opinion through a HIPAA-compliant video platform when a more detailed review of medical history is needed.
No matter where you are in your journey, we’re here to support you with trusted information, compassionate care, and clinical expertise.
ADVOCACY AND POLICY
CLL Society Supports Clinical Trial Modernization
CLL Society Supports Need for Legally Binding Framework for FDA in Rare Diseases
Designing Part B MFP Effectuation to Preserve Access for Patients with Rare Cancers
CLL Society organized a letter to the CMS arguing the agency use its discretion to implement certain IRA provisions so as to support its patients.
CLL Society Endorses Continued Funding for the NIH
CLL Society Supports Need for Legally Binding Framework for FDA in Rare Diseases
UPCOMING EVENTS
Wednesday, August 26, 2026, at 12:30 PM PT / 3:30 PM ET
Join CLL Society for the webinar Understanding the Numbers: A Patient’s Guide to CLL / SLL Testing and Imaging. This webinar will provide a practical overview of the most common tests used in CLL / SLL care and help participants better understand what the results may mean. Discussion will include interpreting blood work and lab results, MRD (measurable residual disease) testing, mutation and genetic testing, imaging scans such as CT, MRI, and PET scans, bone marrow biopsies, and why certain tests are important before starting treatment.
On-Demand Replay
If you missed the recent Q&A-style virtual event “Ask Me Anything” with Dr. Joanna Rhodes and patient advocate Jeff Folloder, you can catch the replay and find the transcript here!
If you missed the recent webinar with William A. Werbel, MD, PhD and Brian Koffman, MDCM (retired) MS Ed on Protecting Against Infections When Your Immunity Is Impaired, catch the replay, presentation slides, and transcript here! Watch now!
Treatment Updates
Real-World Outcomes of Liso-Cel (CAR-T) for CLL
In the real world, patients with CLL treated with liso-cel (CAR-T) have response rates that are just as good or even higher than those seen in clinical trials.
An Update on Sonrotoclax Plus Zanubrutinib for CLL
First-line treatment of CLL with sonrotoclax plus zanubrutinib produced quick, deep remissions in almost all patients by 96 weeks.
Use of Supplements in CLL / SLL
Supplements are not generally recommended unless used to correct a documented deficiency.
Equitable Access and Regulatory News
FDA Approves Sonrotoclax for Mantle Cell Lymphoma
On May 13, 2026, the FDA approved sonrotoclax (Beqalzi from BeOne), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL).
FDA Approves Combo of Acalabrutinib and Venetoclax in CLL
The FDA has approved acalabrutinib and venetoclax as the first all oral combination for previously untreated CLL patients based on the AMPLIFY trial data.
FDA Okays Pirtobrutinib Post Covalent BTKi Treatment
On Dec. 3, 2025 the FDA gave full approval to pirtobrutinib for use in chronic lymphocytic leukemia (CLL) after treatment with a covalent BTK inhibitor.